International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in WHO Drug Information, e.g., for List 62 Prop. INN not later than 31 May 1990.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INN. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will be neither revised nor included in the Cumulative Lists of INN.

Proposed International Nonproprietary Names (Prop. INN): List 62

---

Comprehensive information on the INN programme can be found in WHO Technical Report Series, No. 561, 1975 (Nonproprietary Names for Pharmaceutical Substances: twentieth report of the WHO Expert Committee), ISBN 92 4 1200571 (price: Sw. fr. 3.–) an account of this publication will be found in Annex 2 of the present List. All names from Lists 1–56 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in International Nonproprietary Names (INN) for Pharmaceutical Substances: Cumulative List No. 7, 1988, World Health Organization, Geneva (ISBN 92 4 1185640) (price: Sw. fr. 85.–). This publication consists in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN) in Latin, English, French, Russian, and Spanish—published up to March 1988. The protocol also indicates in which of the 59 individual lists of proposed names and 27 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulas and Chemical Abstracts Service registry numbers. For easy reference, national nonproprietary names that differ from INN, molecular formulas, and Chemical Abstracts Service registry numbers are indexed in a series of annexes. A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French.

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of WHO Drug Information Orders from countries where sales agents have not yet been appointed may be addressed to: World Health Organization, Distribution and Sales Service, 1011 Geneva 27, Switzerland.

---


2 Other lists of proposed and recommended international nonproprietary names can be found in Cumulative List No. 7, 1988.
**Proposed International**

**Nonproprietary Name (Latin, English)**

**Chemical Name or Description, Molecular and Graphic Formulae**

**Chemical Abstracts Service (CAS) registry number**

**Action and use**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Molecular Formula</th>
<th>CAS Number</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>acidum risedronicum</strong>&lt;br&gt;<strong>risedronic acid</strong></td>
<td>[1-hydroxy-2-(3-pyridyl)ethylidene]diphosphonic acid</td>
<td>C₁₀H₁₂NO₇P₂</td>
<td>105462-24-6</td>
<td>Calcium regulator</td>
</tr>
<tr>
<td><strong>actantum</strong>&lt;br&gt;<strong>actarit</strong></td>
<td>(p-acetamidophenyl)acetic acid</td>
<td>C₁₅H₁₅NO₃</td>
<td>18699-02-0</td>
<td>Immunomodulator</td>
</tr>
<tr>
<td><strong>aloracetamum</strong>&lt;br&gt;<strong>aloracetam</strong></td>
<td>N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide</td>
<td>C₁₄H₁₄N₂O₅</td>
<td>119610-26-3</td>
<td>Nootropic agent</td>
</tr>
<tr>
<td><strong>alpratemonum</strong>&lt;br&gt;<strong>alpratene</strong></td>
<td>(±)-3-[2-hydroxy-3-(tert-pentylamino)propoxy]-4-methoxyphenyl]-4'-methylpropophenone</td>
<td>C₂₅H₂₅NO₅</td>
<td>124316-02-5</td>
<td>Antidysrhythmic</td>
</tr>
<tr>
<td><strong>ataprostum</strong>&lt;br&gt;<strong>ataprost</strong></td>
<td>(+)-(2E,3aS,4R,5R,6aS)-4-[(1E,3S)-3-cyclopentyl-3-hydroxypropenyl]-3,3a,4,5,6,6a-hexahydro-6-hydroxy-4-oxo-4H-pentalenevaleric acid</td>
<td>C₂₃H₃₂O₄</td>
<td>83997-19-7</td>
<td>Platelet aggregation inhibitor</td>
</tr>
</tbody>
</table>
batoprazinum 8-(1-piperazinyl)coumarin  
C_8H_8N_2O_2  105685-11-8  psychotropic

bifentanilum  cle-N-{1-[2-(4-ethyl-5-oxo-2-tetrazol-1-yl)ethy]-3-methyl-4-piperidyl]-2-fluoro-2-methoxyacetanilide  
C_26H_28FNO_3  101345-71-5  narcotic analgesic

butenafinum  N-(p-tert-butylbenzy])-N-methyl-1-naphthalinemethylamine  
C_29H_26N  101826-21-1  antifungal

candoxatrilatum  (uS)-1-([carboxycyclohexyl]carbamoyl)-\gamma-[2-methoxythoxy]methyl]-cyclopentanepronic acid  
C_29H_28NO_5  123122-54-3  antihypertensive
Proposed international \hspace{1cm} Chemical Name or Description, Molecular and Graphic Formulae
Nonproprietary Name (Latin, English) \hspace{1cm} Chemical Abstracts Service (CAS) registry number
Action and use

Candoxatrilum
Candoxatril
\[ \text{[eSi-1-[(cis-4-carboxycyclohexyl)carbamoyl]-α-[(2-methoxyethoxy)methyl]cyclopentanepropionic acid, α-5-indany ester}} \]
\[ \text{C}_{22}\text{H}_{31}\text{NO}_{7} \]
123122-55-4 \hspace{1cm} \text{antihypertensive}

Cericlamnum
Cericlamine
\[ \text{(±)-3,3,4-dichlorophenyl]-2-[dimethylamino]-2-methyl-1-propanol} \]
\[ \text{C}_{13}\text{H}_{17}\text{Cl}_{2}\text{NO} \]
112922-55-1 \hspace{1cm} \text{antidepressant}

Ciclosonidum
Ciclosonide
\[ \text{11β,16α,17-tetrahydroxyprogna-1,4-diene-3,20-dione, cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate} \]
\[ \text{C}_{26}\text{H}_{34}\text{O}_{7} \]
\text{glucocorticosteroid}

Daniquidumonum
Daniquidone
\[ \text{8-aminosindolo[1,2-b]quinazolin-12(10H)-one} \]
\[ \text{C}_{21}\text{H}_{18}\text{N}_{2}\text{O} \]
67199-65-0 \hspace{1cm} \text{antineoplastic}
Proposed International Nonproprietary Name (Latin, English) | Chemical Name or Description, Molecular and Graphic Formulae | Chemical Abstracts Service (CAS) registry number | Action and use
---|---|---|---
dapropterin | (-)-(S,R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(3H)-pteridinone | 62989-33-7 | antihyperphenylalaninaemic

desfluranum | (±)-difluoromethyl 1,2,2,2-tetrafluoroethyl ether | C₂H₂F₅O | 57041-87-5 | general anaesthetic

devazepidum | (S)-N-[2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]methyl-2-carboxamide | C₂H₁₅N₂O₄ | 103420-77-5 | cholecystokinin receptor antagonist

dexrazoxanum | (+)-(S)-4,4'-propylenedi-2,6-piperazinedione | C₁₁H₁₄N₂O₄ | 24584-98-6 | antineoplastic

<table>
<thead>
<tr>
<th>Proposed International Nonproprietary Name (Latin, English)</th>
<th>Chemical Name or Description, Molecular and Graphic Formulae</th>
<th>Chemical Abstracts Service (CAS) registry number</th>
<th>Action and use</th>
</tr>
</thead>
</table>
| dosmalfatum | [l-
\(
\beta
\)-d-glucuronic acid-O-6-sulfates][8-]tetracontahydroxyhexadecaaluminum | C_{26}H_{46}Al_{14}O_{73}S_4 | 122312-55-4 | antacid |
| dosmalflate | | | | |
| duteplasum | 245-methionineplasminogen activator (human tissue-type 2-chain form protein moiety) | C_{272}H_{417}N_{113}O_{224}S_{66} | 120608-46-0 | thrombolytic |
| dutoplasme | | | | |
| ecochroamistum | N-\-
\alpha
-methionylcolony-stimulating factor 2 (human U937 cell protein moiety reduced) | | 123120-99-0 | immunostimulant |
| ecochramostin | | | | |
| elsamiricium | 10-[[2-O[2-amino-2,3-dideoxy-3-0-methyl-galactopyranosyl]-6-deoxy-3-0methyl-\-
\beta
-galactopyranosyl[oxy]-6-hydroxy-1-methylbenzo[\-\]
\[1\]-benzopyran[5,4,3-cde][1]benzopyran-5,12-dione | C_{39}H_{13}N_{5}O_{13} | 37088-30-9 | antineoplastic |
| elsamirin | | | | |
| epoetinum alfa | 1-165-erythropoietin (human clone \-
\alpha
-HEPOFL13 protein moiety) | C_{90}H_{152}N_{32}O_{79}S_{5} | 113427-24-0 | antianaemic |
| epoetin alfa | | | | |
| epoetinum beta | 1-165-erythropoietin (human clone \-
\alpha
-HEPOFL13 protein moiety), glycoform \-
\beta
<p>| C_{90}H_{152}N_{32}O_{79}S_{5} | 122312-54-3 | antianaemic |</p>
<table>
<thead>
<tr>
<th>Nonproprietary Name (Latin, English)</th>
<th>Chemical Name or Description, Molecular and Graphic Formulae</th>
<th>Action and use</th>
</tr>
</thead>
<tbody>
<tr>
<td>epastigminum</td>
<td>N-demethyl-N-heptylphysostigmine or (3a,5,6aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl heptylcarbamate</td>
<td>acetylcholinesterase inhibitor</td>
</tr>
<tr>
<td>epastigmine</td>
<td><img src="image1" alt="Chemical Structure" /></td>
<td></td>
</tr>
<tr>
<td>yotozimum</td>
<td>(+)-(R)-o-ethyl-N,N-dimethyl-a-[[3,4,5-trimethoxybenzyl]oxy]methyl][benzyl-amine</td>
<td>gastrointestinal agent</td>
</tr>
<tr>
<td>botozine</td>
<td><img src="image2" alt="Chemical Structure" /></td>
<td></td>
</tr>
<tr>
<td>finasteridum</td>
<td>N-tert-butyl-3-oxo-4-aza-5a-androst-1-ene-17β-carboxamide</td>
<td>antineoplastic</td>
</tr>
<tr>
<td>finasteride</td>
<td><img src="image3" alt="Chemical Structure" /></td>
<td></td>
</tr>
<tr>
<td>fluvastatinum</td>
<td>(±)-(3R*,5S*,6E)-7-[3-(p-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptenonic acid</td>
<td>antihyperlipidaemic</td>
</tr>
<tr>
<td>fluvastatin</td>
<td><img src="image4" alt="Chemical Structure" /></td>
<td></td>
</tr>
</tbody>
</table>
Proposed International Nonproprietary Name (Latin, English) | Chemical Name or Description, Molecular and Graphic Formulae | Chemical Abstracts Service (CAS) registry number | Action and use
--- | --- | --- | ---
Fosinoprilat | (4S)-4-cyclohexyl-1-[(hydroxy(4-phenylbutyl)phosphonyl)acetyl]-L-proline | 93399-71-6 | Angiotensin converting enzyme inhibitor
Fosphenytoin | 3-(hydroxymethyl)-5,5-diphenylhydantoin, dihydrogen phosphate (ester) | 90390-81-9 | Antiepileptic
Fosquidone | Benzyl 5,8,13,14-tetrahydro-14-methyl-8,13-dioxobenz[5,6]isoindolo-[2,1-b]isoquinolin-9-yl hydrogen phosphate | 114517-82-1 | Antineoplastic
Gemcitabine | 2'-deoxy-2'-difluorocytidine | 95058-81-4 | Antineoplastic
<table>
<thead>
<tr>
<th>Nonproprietary Name (Latin, English)</th>
<th>Molecule Name or Description, Molecular and Graphic Formulae</th>
</tr>
</thead>
<tbody>
<tr>
<td>grisopamum</td>
<td>1-(m-chlorophenyl)-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine</td>
</tr>
<tr>
<td>grisopam</td>
<td>C_{10}H_{12}ClN_{2}O_{3} 62230-53-3 anxiolytic</td>
</tr>
<tr>
<td>glipalamidum</td>
<td>(+)-5-methyl-N-(p-tolysulfonyl)-2-pyrazoline-1-carboxamide</td>
</tr>
<tr>
<td>glipalamide</td>
<td>C_{12}H_{13}N_{2}O_{3}S 37598-94-0 antidiabetic</td>
</tr>
<tr>
<td>ipazilidum</td>
<td>N-[3-(diethylamino)propyl]-4,5-diphenylpyrazole-1-acetamide</td>
</tr>
<tr>
<td>ipazilide</td>
<td>C_{17}H_{20}N_{2}O 115436-73-2 antidyssrhythmic</td>
</tr>
<tr>
<td>isbutillinum</td>
<td>7-isobutylicothephyline</td>
</tr>
<tr>
<td>isbutilline</td>
<td>C_{10}H_{14}N_{2}O_{2} 90162-60-0 antisthismatic</td>
</tr>
<tr>
<td>litrocinonidum</td>
<td>6o,9-difluoro-11β,16α,17-trihydroxy-3-oxandrosta-1,4-diene-17β-carboxylic acid, ester with ethyl (S)-1-hydroxyethyl carbonate, cyclic (4R)-16,17-acetal with butyraldehyde</td>
</tr>
<tr>
<td>litrocinone</td>
<td>C_{25}H_{34}F_{2}O_{6} 106033-96-9 glucocorticosteroid</td>
</tr>
<tr>
<td>Proposed International Nonproprietary-Name (Latin, English)</td>
<td>Chemical Name or Description, Molecular and Graphic Formulae</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>levetiracetamum</td>
<td>(S)-2-ethyl-2-oxo-1-pyrrolidineacetamide</td>
</tr>
<tr>
<td>levetiracetam</td>
<td>C₇H₁₅N₂O₂</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>lidanserium</td>
<td>(±)-4-[3-[3-[4-(p-fluorobenzoyl)piperidino]propoxy]-4-methoxyphenyl]-2-pyrrolidinone</td>
</tr>
<tr>
<td>lidanserin</td>
<td>C₈H₁₅FNO₃</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>lifibrol</td>
<td>(±)-p-[4-(p-t-tert-butylphenyl)-2-hydroxybutoxy]benzoic acid</td>
</tr>
<tr>
<td>lifibrol</td>
<td>C₂₀H₂₅O₃</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>melquinasum</td>
<td>ethyl 6-ethyl-5,6-dihydro-9-methyl-5-oxo-s-triazolo[1,5-c]quinazoline-2-carboxylate</td>
</tr>
<tr>
<td>melquiniast</td>
<td>C₂₀H₂₅N₄O₂</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Proposed International Nonproprietary Name (Latin, English)</td>
<td>Chemical Name or Description, Molecular and Graphic Formulae</td>
</tr>
<tr>
<td>-----------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>meribendanum meribendan</td>
<td>4,5-dihydro-5-methyl-6-(2-pyrazol-3-yl-5-benzimidazolyl)-3(2H)-pyridazinone</td>
</tr>
<tr>
<td>nardeterolum nardeterol</td>
<td>(±)-α-[[3-(1-benzimidazolyl)-1,1-dimethylpropylamino)methyl]-2-fluoro-4-hydroxybenzyl alcohol</td>
</tr>
<tr>
<td>neltexenxum neltexine</td>
<td>4',5'-dibromo-α-[[trans-4-hydroxy-cyclohexyl]amino]-2-thiophene-carboxy-o-toluidide</td>
</tr>
<tr>
<td>nopolinonum nopolione</td>
<td>(±)-3,4-dihydro-1-methyl-1-(2-pipridinoethyl)-2(1H)-napthaleneone</td>
</tr>
<tr>
<td>nitecaponum nitecapone</td>
<td>3-(3,4-dihydroxy-5-nitrobenzylidene):2,4-pentanedione</td>
</tr>
</tbody>
</table>
oxilofrinox
oxilofrine

**Proposed International Nonproprietary Name (Latin, English)**

**Chemical Name or Description, Molecular and Graphic Formulae**

**CAS registry number**

**Action and use**

erthro-\(p\)-hydroxy-\(\alpha\)\-[1\{-methylamino\}]ethyl\]benzyl alcohol

\(\text{C}_{16}\text{H}_{28}\text{NO}_2\) 365-26-4  sympathomimetic

\(\text{\includegraphics[width=2cm]{oxilofrinox.png}}\)

pancopenidum
pancopenide

\((\pm\)-4-amino-5-chloro-\(\alpha\)-cyclopentyl-N-3-quinoclidinyl-\(\alpha\)-anisamide

\(\text{C}_{12}\text{H}_{16}\text{ClN}_3\text{O}_2\) 121880-80-4  antiemetic, anxiolytic

\(\text{\includegraphics[width=2cm]{pancopenidum.png}}\)

pantoprazolium
pantoprazole

5\{-difluoromethoxy\}-2\{-[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl\}-benzimidazole

\(\text{C}_{16}\text{H}_{16}\text{F}_2\text{N}_2\text{O}_2\text{S}\) 102825-70-7  antiulcer

\(\text{\includegraphics[width=2cm]{pantoprazolium.png}}\)

pibaxizinum
pibaxizine

[2\{-4\{-diphenylmethylenepiperidinoethoxy\}ethoxy\}acetic acid

\(\text{C}_{24}\text{H}_{28}\text{NO}_4\) 82227-39-2  antispasmodic, antihistaminic

\(\text{\includegraphics[width=2cm]{pibaxizinum.png}}\)

pilsicainidum
pilsicainide

\(\text{tetrahydro-1\-H\-pyrrolizino-7\{5\-H\}\-aceto-2\',6\'-xylidide}\)

\(\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_2\) 88069-87-4  antidysrhythmic

\(\text{\includegraphics[width=2cm]{pilsicainidum.png}}\)
quingagolidum
quinagolide

\[(\pm )-N,N-\text{diethyl}-N'-(3R^*,4aR^*,10aS^*)-1,2,3,4,4a,5,10,10a-\text{octahydro}-6-\text{hydroxy}-1-\text{propybenzo}[g\text{quinolin}-3\text{-yl}]\text{sulfamide}\]
\[C_{29}H_{33}N_2O_5S \quad 87066-78-8 \]

\(D_2\text{-dopamine receptor agonist}\)

risotildum
risotilde

\[4'-\text{[isopropyl]-2-(isopropylamino)ethyl}sulfamoyl]methanesulfonamide\]
\[C_{39}H_{39}N_3O_5S_2 \quad 120888-08-6 \]

\(\text{antidysrhythmic}\)

rociclovirum
rociclovir

\[2\text{-amino-9-\text{[2-isoproxy-1-(isoproxymethy)ethoxy]methyl}]purine}\]
\[C_{29}H_{32}N_3O_3 \quad 108436-80-2 \]

\(\text{antiviral}\)

sambiritum
sambritine

\[2,6\text{-diamino-3-(p-fluorobenzyl)pyridine}\]
\[C_{17}H_{12}FN_3 \quad 115911-28-9 \]

\(\text{anti-inflammatory}\)

sarafloxacinum
sarafloxacin

\[6\text{-fluoro-1-(p-fluorophenyl)-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid}\]
\[C_{29}H_{27}F_2N_3O_5 \quad 98105-99-8 \]

\(\text{antibacterial (vet.)}\)
savinprazolum
savinprazole

2-\{[4-(2,2,3,3,4,4,4-heptafluorobutoxy)-2-pyridyl]methyl}sulfinyl-1H-thieno[3,4-d]imidazole
C_{19}H_{14}F_{7}N_{2}O_{2}S_{2} \quad 121617-11-6 \quad antilulcer

secalciferolum
secalciferol

(5Z,7E,24R)-9,10-seccholesta-5,7,10(19)-triene-3β,24,25-trol
C_{34}H_{46}O_{2} \quad 55721-11-4 \quad calcium regulator

sezolamicum
sezolamide

[+]-\{(5)-5,6-dihydro-4-(isobutylamino)-4H-thieno[2,3-b]thiopyran-2-sulphonamide \}
7,7-dioxide
C_{17}H_{14}N_{2}O_{3}S_{2} \quad 123938-22-5 \quad carbonic anhydrase inhibitor

sobuzoxanum
sobuzoxane

4,4′-ethylenbis[1-(hydroxymethyl)-2,6-piprazinedione] bis(isobutyl carbonato) (ester)
C_{29}H_{30}N_{4}O_{4} \quad 98631-95-9 \quad antineoplastic
<table>
<thead>
<tr>
<th>Name</th>
<th>Chemical Name or Description, Molecular and Graphic Formulae</th>
</tr>
</thead>
<tbody>
<tr>
<td>somalapor</td>
<td>N-carboxyglycinogrowth hormone (pig clone pPGH-1 reduced)</td>
</tr>
<tr>
<td>somalapor</td>
<td>C_{91}H_{127}N_{26}O_{32}S_{7}  108282-98-8  growth hormone</td>
</tr>
<tr>
<td>somenoporum</td>
<td>C_{81}H_{123}N_{28}O_{32}S_{7}  119693-74-2  growth hormone</td>
</tr>
<tr>
<td>thirdinum</td>
<td>3-(2-amino-4-chlorophenyl)-2-iminothiazolidine</td>
</tr>
<tr>
<td>timirdine</td>
<td>C_{7}H_{8}C_{5}N_{3}S  100417-09-2  antidepressant</td>
</tr>
<tr>
<td>tiracizium</td>
<td>ethyl 5-(N,N-dimethylglycyl)-10,11-dihydro-5H-dibenzo[b,f]azepine-3-carboxylate</td>
</tr>
<tr>
<td>tiracizine</td>
<td>C_{17}H_{24}N_{2}O_{4}  83275-55-3  antidyssrhythmic</td>
</tr>
<tr>
<td>trelarizium</td>
<td>(E)-1-[bis(p-fluorophenyl)methyl]-4-(3,4-dimethoxyanisyl)piperazine</td>
</tr>
<tr>
<td>trelarizine</td>
<td>C_{18}H_{12}F_{2}N_{2}O_{5}  123208-82-7  vasodilator</td>
</tr>
</tbody>
</table>
**Proposed International Nonproprietary Name (Latin, English)**

**Chemical Name or Description, Molecular and Graphic Formulas**

**Chemical Abstracts Service (CAS) registry number**

**Action and use**

**troisetronum**
**troisetron**

1H,5aH-tropan-3a-yl indole-3-carboxylate

\[\text{C}_{12}\text{H}_{15}\text{N}_{5}\text{O}_{2}\]

89565-66-4

serotonin antagonist

**vapreotidum**
**vapreotide**

\text{tryptophanamide cyclic (2→7)-disulfide}}\)

\[\text{C}_{69}\text{H}_{104}\text{N}_{40}\text{O}_{32}\text{S}_{2}\]

103222-11-3

antineoplastic

**zatebradnum**
**zatebradine**

\(3\{3-(3,4\text{-dimethoxyphenethyl)methylamino}\text{propyl}i-1,3,4,5\text{-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one}}\)

\[\text{C}_{38}\text{H}_{48}\text{N}_{40}\text{OS}_{2}\]

89175-67-3

bradycardic agent
Names for Radicals and Groups

Some substances for which a proposed international non-
proprietary name has been established may be used in
the form of salts or esters. The radicals or groups involved
may be of complex composition and it is then inconvenient
to refer to them in systematic chemical nomenclature. Con-
sequently, shorter nonproprietary names for some radicals
and groups have been de-
vised or selected, and they are
suggested for use with the
proposed international non-
proprietary names.

bezomilum
bezomil

(phenylmethyl)
C₈H₅C(O)CH₃

erburnum
erbume

tert-butylamine
C₄H₁₀N

hyclas
hyclate

monohydrochloride hemiethanolate hemihydrate
\( \frac{1}{2} \) \( \sum \) C₄H₉Cl₂O₆
\( + \) (OH) C₄H₉OH-H₂O
AMENDMENTS TO PREVIOUS LISTS


Proposed International Nonproprietary Names (Prop. INN): List 6
p. 105 lauralcon chloride
lauralconum chloride
replace the chemical name by the following:
benzy[2-[[p-(lauryl)]phenoxy]ethyl]dimethylammonium chloride

WHO Chronicle, Vol. 18, No. 11, 1964

Proposed International Nonproprietary Names (Prop. INN): List 14
p. 434 benzethionide
benzethimide
replace the CAS registry number by the following:
119391-55-8

Supplement to WHO Chronicle, Vol. 38, No. 4, 1984

Proposed International Nonproprietary Names (Prop. INN): List 52
p. 10 etomoxire
etomoxir
replace the chemical name by the following:
(+ Lactyl)-6-[[p-(chlorophenoxy)hexyl]glycinate


Proposed International Nonproprietary Names (Prop. INN): List 58
p. 182 isamolinum
isamoln
replace the CAS registry number by the following:
118861-00-8


Proposed International Nonproprietary Names (Prop. INN): List 59
p. 9 mandipine
mandipine
replace the CAS number by the following:
120092-68-4

p. 9 murodermin
murodermin
replace the graphic formula by the following:

p. 10 nebrazetam
nebrazetam
replace the CAS number by the following:
116041-13-5

p. 10 ondansetron
ondansetron
replace the Chemical Abstracts Number by the following:
116002-70-1
Proposed International Nonproprietary Names (Prop. INN): List 61

p. 88  bakeprofen  replace the CAS registry number by the following:
bakeprofen  117819-25-7

p. 89  carboxifrolum  replace the action and use statement by the following:
carboxicrolide  D₂ dopaminergic receptor agonist

p. 95  gevotrolimun  replace the chemical name by the following:
evotroline  8-fluoro-2,3,4,5-tetrahydro-2-{[3-(3-pyridyl)propyl]-1H-pyrido[4,3-b]indole

p. 98  notal borocaptate (¹⁴⁶Br)  replace the molecular formula by the following:
sodium borocaptate (¹⁴⁶Br)  ¹⁴⁶BrH₂₂Na₂S

105  ceproziulum  replace the graphic formula by the following:

Procedure and Guiding Principles
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will from now on be reproduced in uneven numbers of proposed INN lists only.